All In Biotech

Drug Trial Radar · NCT04410978

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio®) in Participants With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 974 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

974

Actual

Start

Jun 30, 2020

Primary completion

Jul 15, 2024

Study completion Jul 15, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance and quality of life To evaluate the safety and tolerability of daily SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 and relevant metabolites and its relationship to efficacy and safety To evaluate pharmacodynamics (PD) of SAR442168

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • TolebrutinibDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • TeriflunomideDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • Placebo to match TolebrutinibDrug

    Pharmaceutical form: Tablet Route of administration: Oral

  • Placebo to match TeriflunomideDrug

    Pharmaceutical form: Tablet Route of administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Relapse Rate (ARR) as Assessed by Confirmed Protocol-defined Adjudicated RelapsesTime frame: Baseline (Day 1) to approximately 48 months

Locations

179 sites in 24 countries. Site status is shown where the registry gives one.

  • University of Alabama MS Center-Site Number:8400013

    Birmingham, Alabama

  • University of San Francisco, Sandler Neurosciences Center-Site Number:8400137

    San Francisco, California

  • University of Colorado-Site Number:8400012

    Aurora, Colorado

  • Georgetown University Medical Center-Site Number:8400119

    Washington D.C., District of Columbia

  • Beth Israel Deaconess Medical Center-Site Number:8400064

    Fort Myers, Florida

  • Axiom Clinical Research of Florida-Site Number:8400001

    Tampa, Florida

  • University of South Florida-Site Number:8400006

    Tampa, Florida

  • Meridian Clinical Research-Site Number:8400003

    Savannah, Georgia

  • Consultants In Neurology-Site Number:8400011

    Northbrook, Illinois

  • Tufts Medical Center-Site Number:8400072

    Boston, Massachusetts

  • Michigan Institute For Neurological Disorders-Site Number:8400058

    Farmington Hills, Michigan

  • The Memorial Hospital-Site Number:8400033

    Owosso, Michigan

  • Sharlin Health & Neurology-Site Number:8400093

    Ozark, Missouri

  • Missouri Baptist Medical Center-Site Number:8400019

    St Louis, Missouri

  • Meridian Clinical Research, LLC-Site Number:8400005

    Raleigh, North Carolina

  • Wake Forest University Baptist Medical Center-Site Number:8400116

    Winston-Salem, North Carolina

  • The Ohio State University Wexner Medical Center-Site Number:8400150

    Columbus, Ohio

  • Optimed Research, LTD-Site Number:8400147

    Columbus, Ohio

  • Columbus Neuroscience-Site Number:8400010

    Westerville, Ohio

  • Oklahoma Medical Research Foundation-Site Number:8400018

    Oklahoma City, Oklahoma

  • Providence Multiple Sclerosis Center-Site Number:8400020

    Portland, Oregon

  • University of Texas Southwestern Medical Center-Site Number:8400077

    Dallas, Texas

  • Multiple Sclerosis Center, Swedish Neuroscience Institute-Site Number:8400121

    Seattle, Washington

  • Investigational Site Number :0400004

    Linz, Austria

  • Investigational Site Number :1120005

    Vitebsk, Belarus

  • Investigational Site Number :1120004

    Vitebsk, Belarus

  • Investigational Site Number :1000002

    Pleven, Bulgaria

  • Investigational Site Number :1000005

    Plovdiv, Bulgaria

  • Investigational Site Number :1000004

    Sofia, Bulgaria

  • Investigational Site Number :1000008

    Sofia, Bulgaria

  • Investigational Site Number :1000001

    Sofia, Bulgaria

  • Investigational Site Number :1000006

    Sofia, Bulgaria

  • Investigational Site Number :1000009

    Sofia, Bulgaria

  • Investigational Site Number :1240016

    Vancouver, British Columbia, Canada

  • Investigational Site Number :1240003

    Ottawa, Ontario, Canada

  • Investigational Site Number :1240013

    Toronto, Ontario, Canada

  • Investigational Site Number :1240006

    Gatineau, Quebec, Canada

  • Investigational Site Number :1560022

    Baotou, China

  • Investigational Site Number :1560006

    Beijing, China

  • Investigational Site Number :1560010

    Beijing, China

Showing 40 of 179 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.